Madrigal Pharmaceuticals

Madrigal’s MASH drug sales again top Wall Street projections
BioPharma Dive
Thu, 05/1/25 - 10:13 pm
Madrigal Pharmaceuticals
Rezdiffra
earnings
MASH
Launch metrics of Madrigal's MASH drug Rezdiffra track 'exceptionally well,' CEO says
Fierce Pharma
Thu, 02/27/25 - 09:16 pm
Madrigal Pharmaceuticals
Rezdiffra
MASH
Why Madrigal stock is sinking today
Motley Fool
Mon, 01/13/25 - 05:38 pm
Madrigal Pharmaceuticals
earnings
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
Clinical Trials Arena
Tue, 10/22/24 - 11:29 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
clinical trials
How Madrigal plans to win on the market with the first MASH drug
Pharma Voice
Thu, 10/10/24 - 09:51 am
Madrigal Pharmaceuticals
MASH
Rezdiffra
Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst
Fierce Pharma
Thu, 08/8/24 - 11:15 am
Madrigal Pharmaceuticals
Rezdiffra
MASH
‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra despite VA hurdle
Fierce Pharma
Tue, 05/7/24 - 06:28 pm
Madrigal Pharmaceuticals
Rezdiffra
MASH
NASH
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
BioSpace
Mon, 03/18/24 - 11:25 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
MASH
Madrigal wins FDA approval of first drug for MASH
BioPharma Dive
Thu, 03/14/24 - 06:27 pm
Madrigal Pharmaceuticals
FDA
Rezdiffra
MASH
NASH
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
2 Rising Biotechs That Could Become the Next Novo Nordisk
Motley Fool
Mon, 01/29/24 - 11:04 am
Novo Nordisk
Madrigal Pharmaceuticals
Viking Therapeutics
NASH
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
BioSpace
Fri, 09/29/23 - 11:58 am
Madrigal Pharmaceuticals
NASH
resmetirom
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Tue, 09/12/23 - 10:34 am
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
Wed, 08/23/23 - 10:06 am
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
Thu, 08/10/23 - 09:54 am
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences

Pages